Medline Inc. (MDLN)
| Market Cap | 52.30B |
| Revenue (ttm) | 30.68B +11.9% |
| Net Income | 573.00M -55.3% |
| EPS | 0.65 +800.1% |
| Shares Out | 1.32B |
| PE Ratio | 60.99 |
| Forward PE | 26.14 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 14,245,797 |
| Open | 40.21 |
| Previous Close | 40.35 |
| Day's Range | 38.93 - 41.60 |
| 52-Week Range | 31.37 - 50.88 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 44.31 (+11.44%) |
| Earnings Date | Nov 4, 2026 |
About MDLN
Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. It operates through two segments: Medline Brand and Supply Chain Solutions. The Medline Brand segment procures and manufactures products from three product categories include surgical solutions, front line care, and laboratory and diagnostics. Its front line care offers med-surg products for patient-facing needs, including wound care products, exam g... [Read more]
Financial Performance
In 2025, Medline's revenue was $28.43 billion, an increase of 11.47% compared to the previous year's $25.51 billion. Earnings were $1.16 billion, a decrease of -3.42%.
Financial StatementsAnalyst Summary
According to 27 analysts, the average rating for MDLN stock is "Buy." The 12-month stock price target is $44.31, which is an increase of 11.44% from the latest price.
News
Medline price target raised to $49 from $43 at UBS
UBS raised the firm’s price target on Medline (MDLN) to $49 from $43 and keeps a Buy rating on the shares.
Medline price target raised to $44 from $38 at Evercore ISI
Evercore ISI raised the firm’s price target on Medline (MDLN) to $44 from $38 and keeps an Outperform rating on the shares.
Medline price target raised to $44 from $42 at Baird
Baird raised the firm’s price target on Medline (MDLN) to $44 from $42 and keeps an Outperform rating on the shares.
Medline price target raised to $47 from $45 at Citi
Citi raised the firm’s price target on Medline (MDLN) to $47 from $45 and keeps a Buy rating on the shares. The firm updated the company’s model post the Q3…
Medline Earnings Call Transcript: Q3 2026
Q3 sales and adjusted EBITDA grew strongly, and FY26 sales guidance was raised. Inflation, mix and planned quality and capacity investments weigh on margins, with 2027 EBITDA growth expected below sales growth.
Medline Earnings release: Q3 2026
Medline released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
Medline Slides: Q3 2026
Medline has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 4, 2026.
Medline Quarterly report: Q3 2026
Medline has published its Q3 2026 quarterly earnings report on November 4, 2026.
Medline backs FY26 adjusted EBITDA view $3.3B-$3.4B
The company said, “The Company is raising its full year 2026 outlook for Organic Sales growth to 10.0% to 10.5%, compared to its previous outlook of 9.0% to 10.0%, and…
Medline reports Q3 adjusted EPS 44c, consensus 35c
Reports Q3 revenue $7.86B, consensus $7.72B. “Medline (MDLN) delivered another strong quarter, with double-digit net sales growth, reflecting continued momentum across our business,” said Jim Boyle, c...
Medline Reports Third Quarter and Nine Months 2026 Results
NORTHFIELD, Ill., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (“Medline” or the “Company”) (Nasdaq: MDLN), the largest provider of medical-surgical (“med-surg”) products and supply chain solutions ...
MDLN Investigation Reminder: Medline Product Quality Issues Trigger Securities Fraud Investigation for Investors – Contact BFA Law if You Lost Money
NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Medline Inc. (NASDAQ:MDLN) for potential securities fraud after its ...
Medline announces participation in the 2026 Jefferies Global Healthcare Conference
NORTHFIELD, Ill., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (“Medline”) (Nasdaq: MDLN) today announced that Jim Boyle, chief executive officer, is scheduled to present at the Jefferies Global Hea...
Medline negative after FDA safely alert on beds reveals two deaths
Medline (MDLN) shares gave up their gains and are now little changed at $32.44.
Medline removes all Medline brand beds, accessories amid fire risk
The FDA announced that it is aware that Medline (MDLN) has issued an Urgent Medical Device Field Safety Notice notifying customers of the discontinuation and market exit of all Medline…
$MDLN Stock Losses: BFA Law Reminds Medline Investors with Losses of the Ongoing Securities Fraud Investigation into Potential Product Quality Misrepresentations
NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Medline Inc. (NASDAQ:MDLN) for potential securities fraud after its s...
MDLN Investigation News: Medline Investors are Notified of the Pending Securities Fraud Investigation – Contact BFA Law if You Lost Money
NEW YORK, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Medline Inc. (NASDAQ:MDLN) for potential securities fraud after its s...
Medline price target lowered to $45 from $48 at Mizuho
Mizuho analyst Steven Valiquette lowered the firm’s price target on Medline (MDLN) to $45 from $48 and keeps an Outperform rating on the shares. The firm sees a “less optimistic”…
MDLN Loss Notice: Medline Investors are Reminded of the Pending Securities Fraud Investigation – Contact BFA Law if You Lost Money
NEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Medline Inc. (NASDAQ:MDLN) for potential securities fraud after its ...
MDLN Investigation Reminder: Medline Investors that Lost Money after the 13% Stock Drop are Notified to Contact BFA Law
NEW YORK, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Medline Inc. (NASDAQ:MDLN) for potential securities fraud after its s...
MDLN Securities Announcement: Medline Investors with Losses may have Rights in an Ongoing Securities Fraud Investigation – Contact BFA Law
NEW YORK, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Medline Inc. (NASDAQ:MDLN) for potential securities fraud after its ...
Medline plans new distribution center in suburb of Detroit
Medline (MDLN) announced plans to open a new distribution center in Van Buren Township, Mich., a suburb of Detroit. “The approximately 800,000-square-foot facility represents a new company investment ...
Medline to build Midwestern network with new 800,000-square-foot facility in Van Buren Township, Mich.
State-of-the-art facility planned to reinforce Medline's supply chain resilience in Michigan NORTHFIELD, Ill., Oct. 15, 2026 /PRNewswire/ -- Medline (Nasdaq: MDLN), the largest provider of medical-sur...
$MDLN Investors: A Securities Fraud Investigation is Pending on behalf of Medline Investors that Lost Money after 13% Stock Drop – Contact BFA Law
NEW YORK, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Medline Inc. (NASDAQ:MDLN) for potential securities fraud after its ...
Medline launches enhanced TrackPoint™ to simplify inventory management for post-acute care
Combines real-time inventory tracking with PointClickCare® integration to reduce manual work and improve supply visibility NORTHFIELD, Ill., Oct. 12, 2026 /PRNewswire/ -- Medline (Nasdaq: MDLN) today ...